Position Statement: Postmenopausal Osteoporosis Treatment Strategies in Korea
10.11005/jbm.2023.30.4.289
- Author:
So Young PARK
1
;
Se Hwa KIM
;
Young-Kyun LEE
;
Jung-Ho SHIN
;
Yong-Chan HA
;
Ho Yeon CHUNG
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea
- Publication Type:Review Article
- From:Journal of Bone Metabolism
2023;30(4):289-295
- CountryRepublic of Korea
- Language:English
-
Abstract:
Classifying patients with osteoporosis according to fracture risk and establishing adequate treatment strategies is crucial to effectively treat osteoporosis. The Korean Society for Bone and Mineral Research has issued a position statement regarding appropriate treatment strategies for postmenopausal osteoporosis. According to previous fragility fracture history, bone mineral density (BMD) test results, fracture risk assessment tool, and several clinical risk factors, fracture risk groups are classified into low, moderate, high, and very-high-risk groups. In high-risk groups, bisphosphonates (BPs) and denosumab are recommended as first-line therapies. Sequential BP treatment after denosumab discontinuation is required to prevent the rebound phenomenon. In the very high-risk group, anabolic drugs (teriparatide or romosozumab) are recommended as a first-line therapy; sequential therapy with antiresorptive agents is required to maintain BMD gain and reduce fracture risk. Fracture risk was reassessed annually, and the treatment plan was determined based on the results, according to the osteoporosis treatment algorithm for fracture risk.
